Estrella Immunopharma (NASDAQ:ESLA) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Estrella Immunopharma (NASDAQ:ESLA) in a research note published on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $16.00 price target on the stock.

Estrella Immunopharma Stock Performance

Shares of NASDAQ ESLA opened at $0.87 on Tuesday. The stock has a market cap of $31.29 million, a PE ratio of -3.33 and a beta of 0.34. The business has a fifty day moving average of $0.91 and a two-hundred day moving average of $0.98. Estrella Immunopharma has a 52-week low of $0.63 and a 52-week high of $1.78.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Estrella Immunopharma stock. Geode Capital Management LLC lifted its holdings in Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 22.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 93,418 shares of the company’s stock after buying an additional 16,862 shares during the quarter. Geode Capital Management LLC owned about 0.26% of Estrella Immunopharma worth $106,000 at the end of the most recent quarter. 0.35% of the stock is currently owned by institutional investors and hedge funds.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.